HSP27 AND HSP70 EXPRESSION IN BIOPSIES FROM BREAST CANCER PATIENTS TREATED WITH ANTHRACYCLINES NEOADJUVANT MONOCHEMOTHERAPY

SB NADIN; MM MONTT GUEVARA; PEDRO DAGUERRE; MARCELA LEUZZI; FRANCISCO E. GAGO; JORGE IBARRA; MA LAZZARO; DANIEL R. CIOCCA; LM VARGAS ROIG

Woods Hole, MA

Congreso; International Congress "Heat Shock Proteins in Cancer and immunology"; 2010

Cell Stress Society International

Heat Shock Proteins (Hsps) may be expressed in human tumors been useful as prognostic markers sometimes. There are in vitro evidences showing that Hsps are involved in doxorubicin (DOX) resistance. Our objective was to determine whether HSP27 and HSP70 expression is predictive/prognostic marker in breast cancer patients treated with neoadjuvant monochemotherapy with DOX or epirubicin (EPI). For this study, 60 patients with locally advanced breast tumors were enrolled, who received 75 mg/m2 of DOX or 120 mg/m2 of EPI during 4 cycles before surgery, and 6 cycles with cyclophosphamide, metothrexate and 5-fluorouracil after surgery. Clinical response was considered: complete (as a total disappearence of all clinical signs), partial (>50% of tumor shrinkage), stable (≤50% of tumor shrinkage), and tumor progression (increase of at least 25% of tumor size). The pathological response was considered complete (absence of invasive carcinoma), microscopic residual disease (